rais fair valu estim cross
threshold profit
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data feb
rate updat feb
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
despit well-establish track record introduc
precis sensor use continu glucos monitor
firm main focu enhanc accuraci cgm
perform may enough fend competit
strength technolog captur impress
slice cgm market howev contend sever
factor histor hinder abil expand cgm
market view bigger opportun moreov
tougher competit abbott could hurt
use larg center among type diabet
penetr estim around partli
relat greater need patient pool versu type
keep closer tab blood glucos read similarli payer
reluct expand reimburs beyond type
popul meant face uphil battl
expand type market
abbott introduc meaning innov
realm think could sway patient away
abbott freestyl libr flash significantli user-friendli
aggress price expect product make
substanti inroad type popul medtron new
insulin pump autom much insulin deliveri
come integr cgm new competit
featur could outweigh improv accuraci stick-fre featur
sensor life new next-gen product
strength innov put compani firm
foot first precis cgm remain materi better
competit product second next-gen
significantli lower cost offer flexibl
improv cost structur well close price gap
freestyl libr firm also move aggress
pharmaci channnel enhanc patient access final
dexcom allianc tandem verili googl
healthcar incub provid opportun firm
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
design commerci continu glucos monitor cgm
system diabet cgm system serv altern tradit
blood glucos meter process compani sell three differ piec
equip sensor transmitt receiv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
rais fair valu estim cross
threshold profit jan
billion modestli exceed estim
billion out-performance immateri
effect valuat nonetheless rais fair
valu estim per share
expand time frame discount
cash flow gener consid firm remain
earli stage commerci
reach point posit earn think fair
lengthen time period think
innov occur last
year continu glucos monitor insulin pump
think pressur opportun
best firm impress technolog
advantag translat precis
monitor read still compel consider
diabet patient eager hear next-
gen initi indic suggest could
significantli improv firm cost structur offer
flexibl close price gap abbott freestyl
libr current leav disadvantag
truli offer substanti cost improv would
valuabl need balanc lower-
margin higher-volum opportun come
expand medicar reimburs well distribut
pharmaci channel
substanti boost fair valu estim
per share expand length time
valuat model cover cash flow
gener consid firm remain earli stage
commerci reach point
posit earn ad anoth five year reflect
firm reach steadi state continu hold
optimist project revenu growth
thank greater penetr cgm market driven
attract price wider patient access
pharmaci robust estim long-term earn
growth assum continu strong adopt
follow next-gen gain ground despit
signific double-digit annual revenu growth last
decad reach profit
firm continu invest build manufactur
footprint sale infrastructur overal forecast
revenu compound-annual-growth-rate slightli higher half
histor norm reflect significantli
larger revenu base line new product
expect partial off-set intens competit
abbott diversifi
rival run delay approv manufactur
constraint abbott gotten past
issu think appeal minim
integr guardian connect cgm abbott
freestyl libr devic lower price point
medicar reimburs offer potenti
user perhap first time sever compel
altern choos
expect reach gross margin
oper margin expect
launch next-gen no-calibr devic
creat verili furthermor facil
launch arizona weigh oper near term
expect support recent medicar
approv remov key barrier kept older
consid relianc singl product
tougher competit abbott give
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
closed-loop insulin pump combin scenario
model revenu compound annual growth rate
next year bear-cas fair valu estim
point think dug moat
similar firm earli stage fast growth
sub-scal oper yet reach profit
expect turn corner cross
black could easili delay thank
moat diagnost stem either switch cost
intang yet creat competit
advantag either area sever reason first
point-of-car diagnost gener face low
switch cost second diagnost dexcom
face difficulti link diagnost healthcar
outcom closer linkag outcom stronger
manufactur negoti payer
recogn made progress front
therapeut indic mean patient
make treatment decis base read without
confirm blood glucos level tradit meter
howev simpli go far enough opinion
key rival offer competit cgm
integr insulin pumpth actual therapeut
deviceand instruct pump much
insulin releas remain far closer
therapi happen cgm enabl
therapi
intang asset often moat sourc diagnost
intellectu properti technic know-how
help develop attract cgm product fact
firm long enjoy edg technolog front
greater accuraci compar
competitor howev manag yet translat
bullish scenario assum intern creat
headwind continu stymi abbott
initi fail gain substanti foothold
space leav opportun solidifi
posit newer product like devic verili
product expand market opportun factori
calibr longer sensor life attract user
previous entic cgm devic given
dynam forecast type diabet patient
type popul transit devic
fast rate furthermor begin valid
type non-intens market particularli
newer verily-partn product allow
compani appeal rapidli grow type market
scenario project revenu compound annual
growth rate next year bull-cas
fair valu estim per share
bear-cas scenario abbott chip away
domin market posit faster expect
anticip abbott strength freestyl libr
type space hurt
target user desir integr cgm nearli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
technolog superior econom profit
think intang asset signific enough
suspect manag made deliber decis
focu gain market share expens
profit weve seen sort competit
price strategi usual employ smaller
competitor seek enter market
well-establish competitor alreadi domin
competit price aid new entrant carv slice
market situat face
claim alreadi hold lion share cgm
market addit dexcom
wide
acknowledg technolog leader even
competitor accur sensor
consist roll improv cgm technolog
sixth-gener product
technolog innov associ market share
leadership usual characterist moati firm
wield price power case weve seen littl
evid translat technolog
superior long-term price power exampl
dexcom earlier sensor last seven day price
per day asp manag
decid hold steadi asp sensor
even though new product last day could
potenti lower revenu higher-margin
consum depend mani current patient
use sensor indic
think face neg moat trend
first long-held ambit penetr sizabl
segment type market need multipl daili
insulin inject could benefit cgm use thu far
payer gener reluct establish
reimburs among group patient
kept limit smaller type market
freestyl libr flash offer similar
featur includ factori calibr fda
approv dose decis howev libr flash
price significantli lower
third also face disadvantag type
market mani cgm user also use
insulin pump allianc
product integr tandem pump offer
pump hold estim
share insulin pump market tandem hold
roughli addit johnson johnson exit
pump busi discontinu manufactur anima
product compat dexcom cgm
encourag patient transit medtron
integr pump cgm system
think meaning hybrid closed-loop innov
attract competit pump user
well convert type pump
multipl daili inject anticip
patient opt medtron guardian cgm
integr pump instead keep two
separ devic monitor pump
final asid tradit rival dexcom
may also need protect flank upstart
senseon produc eversens implant
sensor cgm system approv fda
eversens sensor implant upper arm
worn day elimin need switch
insert new sensor everi day
eversens transmitt secur worn
arm sensor data transmit via smartphon
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
app initi indic
may issu replac eversens
sensor expect new long-wear cgm could
attract type diabet offer less complex
non-diabet normalci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
verili expect less expens offer
thinner profil longer sensor wear time
omedicar decis reimburs
favor develop privat
payer often use medicar benchmark
owhil littl detail initi
verili think great potenti appli tech
expertis data analyt data-intens health
manag diabet partnership could put
step ahead rival
ojohnson johnson decis exit pump
busi direct anima user medtron
ountil privat payer decid expand
reimburs includ type diabet dexcom
larg limit type market
must face behemoth
omor attract price abbott
could substanti cut adopt rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
cash flow posit six consecut
year well posit move posit earn
territori revenu grown quickli
research develop expens sell gener
administr cost grown significantli well
sometim outpac revenu growth earli
phase commerci think
inflect point begin post
meaning profit histor fund
oper loss addit capit rais
year convert debt took
substanti debt rel histor level
issu million convert senior note
matur intent financ
signific expans particularli buildout
compani manufactur facil arizona note
initi convers rate share common stock
per princip amount note equat
per share common stock recent
firm issu million convert debt due
partial redeem convert debt come due
note initi convers rate
equival per share also issu
million share rais fund pay hefti
consid relianc singl product
current inabl consist earn profit tougher
competit abbott give dexcom
high uncertainti rate dexcom greatest materi risk
better-than-expect adopt competit product
opinion alreadi expect strong adopt
abbott freestyl libr flash
guardian cgm market recept exce
optimist expect would bear brunt
addit pure play cgm opportun
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi well-being sole base growth one
type product unlik main competitor wide
diversifi progress abbott might make
expand reimburs could also hurt
share longer term doubt
whether technolog leadership enough
allow commerci success continu believ
type type intens diabet continu
seek product improv well-b make
solid underli demand howev think may
cede market share abbott
product improv accuraci offer addit featur
asid competit risk
also face gener medic devic risk
includ run afoul fda potenti product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
board director
repres date owner name posit common share held report holder issuer
global internet thing etf
fidel manag research compani
capit research manag compani
share
fund
share
fund
gregg serv ceo eventu step
serv execut chairman role
maintain today former kevin sayer becam ceo
interest gregg sayer previous
serv role minim diabet manag system
acquir billion
believ experi may give manag team
valuabl insight diabet market
think manag long-term focu innov
sound like reach
creat strateg partnership busi
alphabet life scienc divis verili priorit
watch applaud manag invest creat
digit ecosystem around cgm data particularli
cgm info fed io android devic manag
diabet extrem data intens well suit
app would equip patient act cgm
read time manner also like
partner integr cgm energet pump
maker tandem well
gorilla insulin pump
littl critic firm capit alloc
perspect remain earli stage
commerci high growth technolog
adopt manag continu invest next
improv strateg
allianc time posit
face decis alloc excess cash
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fair valu estim per share
howev continu think stock significantli
overvalu stand behind no-moat rate
could shift think neg moat
trend see convinc evid firm move
strengthen alreadi notabl technolog advantag
think dexcom rival abbott decis penetr
pharmaci channel correspondingli decis
privat payer classifi continu
glucos monitor pharmaci benefit could open
door signific growth cgm penetr thank
lower price conveni access greater
willing physician prescrib cgm penetr
among patient type diabet grown
steadili remain roughli expect
penetr could grow significantli spur
explos innov made
user-friendli greater access grow bodi
clinic evid support use
major drawback pharmaci strategi lower
price amount substanti price headwind
patient mix shift reflect
user pharmaci thu far impact
manag firm seek reduc manufactur
cost greater autom howev remain
earli day headwind full impact like
wont seen late year even earli
nevertheless anticip strategi deliv
greater volum growth off-set price declin
rais fair valu estim cross
threshold profit jan
billion modestli exceed estim
billion out-performance immateri
effect valuat nonetheless rais fair
valu estim per share
expand time frame discount
cash flow gener consid firm remain
earli stage commerci
reach point posit earn think fair
lengthen time period think
innov occur last
year continu glucos monitor insulin pump
think pressur opportun
best firm impress technolog
advantag translat precis
monitor read still compel consider
diabet patient eager hear next-
gen initi indic suggest could
significantli improv firm cost structur offer
flexibl close price gap abbott freestyl
libr current leav disadvantag
truli offer substanti cost improv would
valuabl need balanc lower-
margin higher-volum opportun come
expand medicar reimburs well distribut
pharmaci channel
push pharmaci channel boost
take anoth look potenti new
effort establish distribut pharmaci
channel versu durabl medic equip distributor
histor reli upon substanti boost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
